- Home
- AVXL vs NGNE Comparison
AVXL vs NGNE Comparison
Compare AVXL & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVXL
- NGNE
- Stock Information
- Founded
- AVXL 2004
- NGNE 2003
- Country
- AVXL United States
- NGNE United States
- Employees
- AVXL N/A
- NGNE N/A
- Industry
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- AVXL Health Care
- NGNE Health Care
- Exchange
- AVXL Nasdaq
- NGNE Nasdaq
- Market Cap
- AVXL 484.2M
- NGNE 471.1M
- IPO Year
- AVXL N/A
- NGNE N/A
- Fundamental
- Price
- AVXL $7.45
- NGNE $34.52
- Analyst Decision
- AVXL Strong Buy
- NGNE Strong Buy
- Analyst Count
- AVXL 2
- NGNE 6
- Target Price
- AVXL $43.00
- NGNE $63.80
- AVG Volume (30 Days)
- AVXL 1.6M
- NGNE 353.3K
- Earning Date
- AVXL 11-25-2024
- NGNE 11-15-2024
- Dividend Yield
- AVXL N/A
- NGNE N/A
- EPS Growth
- AVXL N/A
- NGNE N/A
- EPS
- AVXL N/A
- NGNE 0.18
- Revenue
- AVXL N/A
- NGNE $925,000.00
- Revenue This Year
- AVXL N/A
- NGNE N/A
- Revenue Next Year
- AVXL N/A
- NGNE N/A
- P/E Ratio
- AVXL N/A
- NGNE $189.06
- Revenue Growth
- AVXL N/A
- NGNE N/A
- 52 Week Low
- AVXL $3.25
- NGNE $12.49
- 52 Week High
- AVXL $10.45
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- AVXL 54.68
- NGNE 35.74
- Support Level
- AVXL $7.55
- NGNE $35.60
- Resistance Level
- AVXL $10.45
- NGNE $43.24
- Average True Range (ATR)
- AVXL 0.84
- NGNE 6.02
- MACD
- AVXL 0.08
- NGNE -2.86
- Stochastic Oscillator
- AVXL 37.77
- NGNE 0.00
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today's complex devastating neurological diseases into treatable conditions.